Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Mitra RxDx is raising $48,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Mallikarjun Sundaram played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mitra RxDx

Mitra Biotech is a global leader in advancing personalized cancer treatment. We are evolving the personalization of treatment selection and drug development through our phenotypic platforms that reliably predict individual response to tested treatment. Founded in 2010, Mitra is headquartered in Woburn, MA and maintains a significant research and laboratory presence in Bangalore, India. We are committed to developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer. To learn more about Mitra RxDx, visit http://www.mitrabiotech.com/

Contact:
Mallikarjun Sundaram, Chief Executive Officer
857-260-8126
msundaram@mitrabiotech.com
https://www.linkedin.com/in/mallik-sundaram-2155851/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved